Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06809803 · ClinicalTrials.gov registry record · Phase 2
Extended-release Sodium Oxybate in Children
A Phase 2 study of Narcolepsy Type 1 (NT 1), sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06809803 is a Phase 2 study of Narcolepsy Type 1 (NT 1) that is actively recruiting participants, run by Stanford University. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06809803, a Phase 2 study of Narcolepsy Type 1 (NT 1), is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objectives of this study are to determine the treatment preferences of children with narcolepsy type 1 between Extended-release sodium oxybate and Non-extended-release oxybates (Sodium oxybate or a medication with the combination of Calcium, magnesium, potassium, and sodium oxybates). The study will also assess the safety, convenience, and tolerability of Extended-release sodium oxybate. Additionally, the researchers aim to assess how well Extended-release sodium oxybate works in treating narcolepsy type 1.
Conditions Studied
Interventions
- DRUG Extended-release sodium oxybate
- DRUG Non-extended-release oxybates
Study Locations (1)
California
- Stanford University - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06809803
The ClinicalTrials.gov registry entry for NCT06809803 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Narcolepsy Type 1 (NT 1) appearing as the primary indexed condition, and to 2 interventions - of which Extended-release sodium oxybate is the first listed.
NCT06809803 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06809803 about?
NCT06809803 is a clinical study titled "Extended-release Sodium Oxybate in Children". The main objectives of this study are to determine the treatment preferences of children with narcolepsy type 1 between Extended-release sodium oxybate and Non-extended-release oxybates (Sodium oxybate or a medication with the combination of Calcium, magnesium, potassium, and sodium oxybates). The s...
What is the current status of trial NCT06809803?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2025-10-27. Estimated completion is 2027-07.
What conditions does trial NCT06809803 study?
This clinical trial studies the following conditions: Narcolepsy Type 1 (NT 1).
What interventions are being tested in trial NCT06809803?
The interventions under investigation include: Extended-release sodium oxybate (DRUG), Non-extended-release oxybates (DRUG).
Who is sponsoring clinical trial NCT06809803?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06809803 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.